News NICE delivers more good news for cervical cancer patients Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.
News NICE says Libtayo can be used for advanced cervical cancer New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.
News Sanofi's type 1 diabetes-delaying drug cleared for NHS use People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.
News AbbVie's migraine drug cleared for migraine attacks on NHS AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News AbbVie's ovarian cancer drug Elahere gets NHS green light AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
News NICE changes stance on Genmab's cervical cancer drug After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.